To use the number of positive growth periods as a characterization of the growth of small renal masses in order to determine potential predictors of malignancy.
Introduction
It is estimated that 62 000 new cases of kidney and renal pelvis cancer are diagnosed annually in the USA [1] . The greatest increase in detection has been seen in small renal masses (clinical stage T1a, ≤4 cm), of which >50% are incidentally discovered [2] . Clinical stage T1a small renal masses are biologically heterogeneous, with most being lowgrade, indolent cancers [3] [4] [5] [6] and up to 20-30% being benign masses [7] . Traditionally, patients with stage I renal masses have undergone surgery, most commonly radical or partial nephrectomy; however, the risk of comorbidities and overtreatment may outweigh the benefits of these surgical interventions, especially in those with reduced life expectancy. For this reason, alternative management strategies have emerged, namely active surveillance, now recognized as a safe alternative for patients with small renal masses [8, 9] .
It is a common belief that growth rate is associated with the malignant potential of small renal masses [10] [11] [12] ; however, studies in patients undergoing active surveillance fail to demonstrate a correlation between overall growth rate and clinical behaviour, indicating that most small renal masses grow slowly regardless of pathology and that both benign and malignant tumours can demonstrate significant growth rates [9, 13, 14] . In the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry, linear growth rate is similar for patients with benign and indolent masses crossing over to surgery from active surveillance [9] . Additionally, data from the Renal Cell Carcinoma Consortium of Canada indicate that oncocytomas can be among the fastest-growing renal masses [15] . Furthermore, it is believed that most tumours grow at a consistent, slow growth rate based on extrapolated growth rates over extended periods of time [10] [11] [12] . Many tumours managed by active surveillance, however, do not grow for an extended period of time and then may grow rapidly [8] , therefore, it is not completely understood whether overall growth rate can be used as an objective correlate to clinical outcomes and whether or not it can be used to follow patients on active surveillance. The aim of the present study was to evaluate the association of tumour growth with unfavourable pathology in a cohort of patients with small renal masses who were imaged at multiple time points prior to surgical resection.
Patients and Methods
The Johns Hopkins Renal Mass Registry was queried for patients who underwent surgical intervention for a clinically localized, solid, enhancing renal mass, <4 cm in diameter on axial imaging. A total of 1 388 patients were identified, of whom 124 (9%) underwent axial imaging at multiple time points with either contrasted CT, MRI or ultrasonography, prior to surgery. This group formed the cohort for the present study.
Patients were categorized by pathology into two groups. Patients with favourable pathology had benign tumours, including angiomyolipomas, oncocytomas, mixed epithelial and stromal tumours and cysts; chromophobe RCCs, and low-grade, pathologically localized (pT1-2) RCC. Patients with unfavourable pathology had high-grade RCC of any stage and low-grade, locally advanced (pT3-4) RCC. Greatest tumour diameter was recorded from radiology reports. Tumours were not remeasured for the purposes of this study so as to replicate clinical practice. One positive growth period was counted each time the difference in greatest tumour diameters between two images was greater than zero. Overall growth rate was calculated as the change in greatest tumour diameter over time between initial image to final image taken and was reported as cm/year.
The relationship between number of positive growth periods and favourability group was analysed using the CochranArmitage test for trend and Somers' D association. These tests were chosen to assess the association between a variable with two categories (favourable or unfavourable pathology) and a variable with x ordered categories (number of positive growth periods ranging from 0 to 4). Statistical significance was set as a two-sided P value of 0.05. All data analyses were performed using SAS, version 9.4 (SAS, Cary, NC, USA).
Results
Of the 124 patients included in this study, 86 [2] [3] ; P = 0.37). Other patient characteristics, including sex, race, tumour laterality, clinical and pathological staging, tumour grading, and tumour subtype are detailed in Table 1 .
The overall tumour growth rate in was higher in the unfavourable group than the favourable group (mean [SD] = 1.6 [2.8] vs. 0.7 [1.7] cm/year); however, this did not reach statistical significance (P = 0.07; Fig. 1 ).
The Cochran-Armitage test showed a significant difference in trend in the number of positive growth periods between favourable and unfavourable pathology groups (P = 0.02). This difference in trend between pathology favourability groups is shown in Table 2 . There was a higher proportion of patients with two, three or four positive growth periods in the unfavourable pathology group compared with the favourable pathology group (15.8%, 7.9% and 5.3% vs 10.5%, 4.7% and 0%, respectively). Those with unfavourable pathology had a lower proportion of zero positive growth periods (15.8% vs 29.1%). The proportion of patients with one positive growth period was similar between favourable and unfavourable pathology groups (55.8% vs 55.3%). The ratio of favourable to unfavourable pathology was 1.8, 1.0, 0.66, 0.59 and 0 as the number of positive growth periods increased from 0 to 4, respectively (Fig. 2) . Somers' D association showed a positive association between increased number of positive growth periods and unfavourable pathology (0.15 [95% CI 0.02, 0.29]). A subset analysis, limited to clinical T1 tumours only (N = 110), revealed similar findings for both overall growth rate and number of positive growth periods (Table S1) .
Discussion
The present retrospective study of patients undergoing surgery for small renal masses showed that overall growth rate was not predictive of favourable or unfavourable pathology. While there was a difference in mean overall growth rate between pathology favourability groups, this did not reach traditional levels of significance. We acknowledge that tumours with unfavourable pathology probably grow faster than those with favourable pathology, but the wide and overlapping variation in linear growth rate (Fig. 1) among histologies makes application of this metric to clinical practice challenging.
Previous data also show the inconsistent nature of using overall growth rates to predict potential for malignancy. The prospective study by the Renal Cell Carcinoma Consortium of Canada has shown that even benign tumours, such as oncocytomas, have the potential to grow fast [15] , which could thereby give a false indication of malignancy [14] . Additionally, data from the DISSRM registry has shown that most small renal masses are observed to grow in spurts and remain quiescent for an extended period of time [9, 16] . If these tumours are assumed to grow in a linear fashion as previous studies indicate, calculating an overall growth rate during a time of quiescence could underestimate the effect of growth rate on tumour malignancy. Likewise, calculating a change in tumour diameter during a growth spurt could give a falsely exaggerated growth rate measurement and therefore prompt immediate intervention. These conflicting findings suggest that overall growth rates may not be as informative of malignant potential as previously thought. Baseline characteristics, such as patient sex and absolute tumour size, are the only variables that have been consistently associated with malignancy for clinically localized renal masses [17] . In the present study, we chose to analyse the number of positive growth periods as a correlate to how these tumours have been observed to grow in a non-linear, stepwise fashion over time. The number of positive growth periods was chosen as a metric to indicate growth. We demonstrate that there is a significant difference in the number of positive growth periods between patients with favourable and unfavourable pathology. Notably, there was a greater proportion of patients who had higher numbers of positive growth periods, or greater persistent growth, in the unfavourable pathology group. While this certainly represents a selection bias, we believe that consistent growth indicates the more aggressive nature of unfavourable tumours, as they continue to grow over a statistically equivalent time interval. It is also important to consider that there was a lesser proportion of patients who had zero positive growth periods in the unfavourable pathology group. Some of the tumours with zero positive growth periods may have even exhibited periods of negative growth, but this was not stratified further in our study.
An additional finding of the present study is that the number of positive growth periods was positively associated with unfavourable pathology. Although we did not determine a specific threshold for the number of positive growth periods that could predict unfavourable pathology, this association establishes the importance of using the number of positive growth periods as a metric in characterizing the growth of small renal masses. Our data suggest that the number of positive growth periods may more accurately characterize the non-linear growth of these small renal masses than overall growth rate and could potentially be a useful tool for managing patients undergoing active surveillance for small renal masses. The number of positive growth periods may be thought of as a potential 'risk count' for renal tumours on active surveillance, similar to a previously suggested framework for prostate cancer biomarkers for active surveillance of prostate cancer [18] .
This then leads us to the question of why a greater number of positive growth periods may indicate a worse prognosis. The immunoediting hypothesis, which describes the three phases in which a tumour can interact with the immune system (elimination, equilibrium and escape), provides a potential answer [19] [20] [21] . While undergoing active surveillance, the growth of small renal masses is slow, on average 1 mm per year [22] ; however, individual tumours often grow in spurts and remain stable for an extended period of time [8] . We hypothesize that the immunoediting hypothesis may be present in clinically localized renal masses and that 'growth spurts' may represent a shift from equilibrium to escape in these masses.
The present study has some limitations. Chief among them is its retrospective design which may have introduced both selection and information bias. Indeed, the study population only included a small subset of patients who have undergone surgery for a renal mass at our institution; thus, the vast majority of patients who only had one image taken were excluded from the study. We acknowledge that the mean time interval before surgical removal of tumours was <1 year in both groups, which is not a long time period for the surveillance of small renal masses. As such, the generalizability of these data to patients on active surveillance is not yet entirely certain. Another limitation is the fact that we used measurement data from varying imaging methods (CT, MRI, ultrasonography), each having their own range of error. Inter-observer variability can also exist between individual radiologists. Thus, any small variations attributable to comparing different imaging techniques or observers may have had some influence on our results. Notably, the effect of this potential variation should be similar between both cohorts (favourable or unfavourable pathology) as the presence of unfavourable pathology was not definitively known until after surgery in the vast majority of cases.
In conclusion, overall growth rate was not predictive of unfavourable pathology in this retrospective study; however, a positive association between number of positive growth periods and unfavourable pathology was observed. Future studies of larger sample size, and ongoing prospective studies may elucidate the importance of the number of positive growth periods as an indicator of malignant potential in patients undergoing active surveillance for small renal masses.
